88628-49-3

Upstream product

• 3470-50-6 6-Hydroxy-1-tetralone 
• 103-63-9 1-phenyl-2-bromoethane 
• 1078-19-9 6-methoxy-3,4-dihydro-1(2H)-naphthalenone 

Downstream Products

• 66361-95-3 6-Phenethyloxy-3,4-dihydro-2H-naphthalen-1-one oxime 
• 66362-11-6 C₂₅H₂₅NO₄S 

Relevant academic research and scientific papers

α-Tetralone derivatives as inhibitors of monoamine oxidase

In the present study, a series of fifteen α-tetralone (3,4-dihydro-2H-naphthalen-1-one) derivatives were synthesised and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B. The α-tetralone derivatives examined are structurally related to a series of chromone (1-benzopyran-4-one) derivatives which has previously been shown to act as MAO-B inhibitors. The results document that the α-tetralones are highly potent MAO-B inhibitors with all compounds exhibiting IC50 values in the nanomolar range (50 values in the nanomolar range (50 value of 4.5 nM with a 287-fold selectivity for MAO-B over the MAO-A isoform, while the most potent MAO-A inhibitor, 6-(3-cyanobenzyloxy)-3,4-dihydro-2H-naphthalen-1-one, exhibits an IC50 value of 24 nM with a 3.25-fold selectivity for MAO-A. Analyses of the structure-activity relationships for MAO inhibition show that substitution on the C6 position of the α-tetralone moiety is a requirement for MAO-A and MAO-B inhibition, and that a benzyloxy substituent on this position is more favourable for MAO-A inhibition than phenylethoxy and phenylpropoxy substitution. For MAO-B inhibition, alkyl and halogen substituents on the meta and para positions of the benzyloxy ring enhance inhibitory potency. It may be concluded that α-tetralone derivatives are promising leads for design of therapies for Parkinson's disease and depression.

α-Tetralone derivatives as inhibitors of monoamine oxidase

In the present study, a series of fifteen α-tetralone (3,4-dihydro-2H-naphthalen-1-one) derivatives were synthesised and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B. The α-tetralone derivatives examined are structurally related to a series of chromone (1-benzopyran-4-one) derivatives which has previously been shown to act as MAO-B inhibitors. The results document that the α-tetralones are highly potent MAO-B inhibitors with all compounds exhibiting IC50 values in the nanomolar range (50 values in the nanomolar range (50 value of 4.5 nM with a 287-fold selectivity for MAO-B over the MAO-A isoform, while the most potent MAO-A inhibitor, 6-(3-cyanobenzyloxy)-3,4-dihydro-2H-naphthalen-1-one, exhibits an IC50 value of 24 nM with a 3.25-fold selectivity for MAO-A. Analyses of the structure-activity relationships for MAO inhibition show that substitution on the C6 position of the α-tetralone moiety is a requirement for MAO-A and MAO-B inhibition, and that a benzyloxy substituent on this position is more favourable for MAO-A inhibition than phenylethoxy and phenylpropoxy substitution. For MAO-B inhibition, alkyl and halogen substituents on the meta and para positions of the benzyloxy ring enhance inhibitory potency. It may be concluded that α-tetralone derivatives are promising leads for design of therapies for Parkinson's disease and depression.

HISTONE DEMETHYLASE INHIBITORS

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

Synthesis of 2-(N-substituted amino)-6-hydroxy-1,2,3,4-tetrahydronaphthalen-1-ol derivatives

trans-6-Hydroxy-2-(1-methyl-3-phenylpropyl)amino-1,2,3,4-tetrahydronaphth alen-1-ol (8a), trans-6-hydroxy-2-(1-methyl-2-phenoxyethyl)amino-1,2,3,4-tetrahydronaphtha len-1-ol (8b) and trans-1,6-dihydroxy-2-(1-methyl-3-phenylpropyl)amino-1,2,3,4-tetrahydronap hthalene-5-carboxamide (9a) were synthesized as a part of our search for useful cardiovascular agents. 2-(N-Substituted amino)-6-alkoxy-1,2,3,4-tetrahydronaphthalen-1-ols (10-31) having various substituents at the 5-, 6- and 7-positions of the naphthalene ring were prepared by a five-step sequence of reactions starting from 3,4-dihydro-1(2H)-naphthalenone derivatives (36). Furthermore 2-(N-substituted amino)-1-indanol derivatives (33) and 6-(N-substituted amino)-2-hydroxy-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ols (34, 35) were obtained by the reductive alkylation of the corresponding amino alcohols with carbonyl compounds. These N-substituted amino alcohols (8-35) were tested for vasodilating activity in anesthetized dogs and for β-blocking activity using isolated guinea pig atrial preparations.